Harrow Inc. targets Melt Pharma buyout to expand sedation portfolio with MELT-300, a sublingual non-IV sedative, aiming for U.S. launch and global partnerships while diversifying beyond ophthalmics. ...
Y-mAbs Therapeutics stunned investors when SERB Pharmaceuticals announced an all-cash bid to take the company private at $8.60 per share, valuing the deal at approximately $412 million. ...
Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning the impending blow from the loss of exclusivity on its ...